Citius Oncology, Inc.
NASDAQ: CTOR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Leonard L. Mazur
- Employees
- 285
- Headquarters
- New York City, United States
- IPO year
- 2022
- Market cap
- $63.7M
- Website
- https://www.citiusonc.com/overview/default.aspx
Loading CTOR…
Loading profile data…Frequently asked questions about CTOR
What does Citius Oncology, Inc. (CTOR) do?
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The fi...
Where does CTOR trade?
Citius Oncology, Inc. (CTOR) trades on the NASDAQ Global Market.
What sector is CTOR in?
Citius Oncology, Inc. (CTOR) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Citius Oncology, Inc.?
Leonard L. Mazur is the chief executive officer of Citius Oncology, Inc. (CTOR).
Where is Citius Oncology, Inc. headquartered?
Citius Oncology, Inc. is headquartered in United States.
Does CTOR pay a dividend?
Citius Oncology, Inc. (CTOR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CTOR go public?
Citius Oncology, Inc. (CTOR) completed its initial public offering in 2022.